Ribavirin Levels in Post Liver Transplant Patients Treated for Recurrent Hepatitis C Viral Infection

Transplantation Proceedings

Volumn 37, Issue 7, 2005, Pages 3190-3196

  Jain, A ^a,b,d   Vekatramanan, R ^c   Yelochan, B ^b   Kashyap, R ^a   Marcos, A ^b   Fung, J ^b  

^a STRONG MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; CREATININE; CYCLOSPORIN; LAMIVUDINE; NELFINAVIR; PROTON PUMP INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TACROLIMUS; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; KIDNEY DYSFUNCTION; LIVER GRAFT; LIVER GRAFT REJECTION; MALE; PATIENT CARE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; RECURRENT INFECTION;

ADULT; AGED; ANTIVIRAL AGENTS; EPOETIN ALFA; FEMALE; HEMATINICS; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN;

EID: 26444461264     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.07.057     Document Type: Article

References (23)

1. UNOS The U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients 2003 Available: http://www.OPTN.org
2. E.J. Gane, N.V. Naoumov, K.P. Qian A longitudinal analysis of hepatitis C virus replication following liver transplantation Gastroenterology 110 1996 167
3. E. Gane Treatment of recurrent hepatitis C Liver Transpl 8 10 Suppl 1 2002 S28
4. T. Poynard, P. Marcellin, S.S. Lee International Hepatitis Interventional Therapy Group (IHIT) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 1998 1426
5. J.G. McHutchison Ribavirin and interferon for recurrent posttransplantation HCV infection to treat or not to treat? Hepatology 26 1997 505
6. A.O. Shakil, B. McGuire, J. Crippin A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C Hepatology 36 2002 1253
7. A.S. Ross, A.K. Bhan, M. Pascual Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C Clin Transplant 18 2004 166
8. D. Samuel, T. Bizollon, C. Feray Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation a randomized study Gastroenterology 124 2003 642
9. J. Dumortier, J.Y. Scoazec, P. Chevallier Treatment of recurrent hepatitis C after liver transplantation a pilot study of peginterferon alfa-2b and ribavirin combination J Hepatol 40 2004 669
10. A. Bruchfeld, K. Lindahl, R. Schvarcz Dosage of ribavirin in patients with hepatitis C should be based on renal function a population pharmacokinetic analysis Ther Drug Monit 24 2002 701
11. A.B. Jain, B. Eghtesad, R. Venkataramanan Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection Liver Transpl 8 2002 1007
12. G.G. Granich, D.J. Krogstad, J.D. Connor High-performance liquid chromatography (HPLC) assay for ribavirin and comparison of the HPLC assay with radioimmunoassay Antimicrob Agents Chemother 33 1989 311
13. D.W. Cockcroft, M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31
14. National Institutes of Health NIH Consensus Statement on Management of Hepatitis C: 2002 NIH Consens State Sci Statements 19 2002 1
15. J. Connor Ribavirin pharmacokinetics Pediatr Infect Dis J 9 9 Suppl 1990 S91
16. J.F. Jen, P. Glue, S. Gupta Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C Ther Drug Monit 22 2000 555
17. M.T.T. Rowland Clinical pharmacokinetics concepts and application 3rd ed. 1995 Williams & Wilkins Baltimore
18. V. Warty, S. Zuckerman, R. Venkataramanan Tacrolimus analysis a comparison of different methods and matrices Ther Drug Monit 17 1995 159
19. M. Homma, A.L. Jayewardene, J. Gambertoglio High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes Antimicrob Agents Chemother 43 1999 2716
20. A.B. Jain, R. Venkataramanan, B. Eghtesad Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients Liver Transpl 9 2003 954
21. A.K. Jain, R. Venkataramanan, J.A. Fridell Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient a case report Liver Transpl 8 2002 838
22. A.K. Jain, R. Venkataramanan, R. Shapiro The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients Liver Transpl 8 2002 841
23. U.A. Walker Update on mitochondrial toxicity where are we now? J HIV 8 2003 32